Please assess the completion status of the following clinical trial:

Trial Title: STI571 ProspectIve RandomIzed Trial: SPIRIT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18 years of age~* Patients with Bcr-Abl positive CML in chronic phase.~* Patients within 14 weeks of diagnosis and previously untreated for CML except for hydroxyurea and/or anagrelide.~* No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly~* ECOG performance score of 0-2~* acceptable hepatic, renal, and cardiac function~* Informed consent signed up~Exclusion Criteria:~* Depressive syndrome not controlled~* Uncontrolled medical illnesses.~* Women with childbearing potential and male patients who are unwilling or unable to use an adequate method to avoid pregancy for the entire period of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imatinib mesylate 400 mg (Type: EXPERIMENTAL): None
- Imatinib mesylate 600 mg (Type: EXPERIMENTAL): None
- Imatinib mesylate 400 mg +Peg interferon (Type: EXPERIMENTAL): None
- Imatinib mesylate 400 mg +Cytarabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).